Prothena Corporation

AI Score

0

Unlock

12.65
-0.48 (-3.66%)
At close: Jan 14, 2025, 3:59 PM
12.67
0.16%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 12.5
Market Cap 680.68M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.46
PE Ratio (ttm) -5.14
Forward PE n/a
Analyst Buy
Ask 15.25
Volume 497,974
Avg. Volume (20D) 559,993
Open 13.36
Previous Close 13.13
Day's Range 12.41 - 13.41
52-Week Range 11.70 - 34.90
Beta undefined

About PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2012
Employees 173
Stock Exchange NASDAQ
Ticker Symbol PRTA

Analyst Forecast

According to 7 analyst ratings, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 247.83% from the latest price.

Buy 71.43%
Hold 28.57%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Prothena Corporation is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $7.53M, reflecting a 2.28K% YoY growth and earnings per share of -1.04, making a -17.46% decrease YoY.
3 weeks ago · Source
+33.97%
Prothena shares are trading higher after the Phase... Unlock content with Pro Subscription
5 months ago · Source
+4.42%
Prothena shares are trading higher after the company reported better-than-expected Q2 financial results.